Scalper1 News
Demand for Regenxbio (RGNX) stock is strong heading into the pricing of its initial public offering, scheduled to occur late Wednesday. Research firm IPOboutique.com says channel checks reveal, according to underwriter guidance, that the deal is now “multiple times oversubscribed.” Regenxbio plans to raise $122 million by offering 5.6 million shares at $22 each. It previously set a price range of 17 to 19. The biotech company developing, Scalper1 News
Scalper1 News